more

Insulet (PODD)

(Real Time Quote from BATS)

$180.43 USD

+8.16 (4.74%)

Updated May 15, 2024 01:32 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	24.20%
2	Buy	18.04%
3	Hold	9.52%
4	Sell	5.20%
5	Strong Sell	2.60%
S&P	500	11.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5 3

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth A Momentum B VGM

Industry Rank:

Bottom 42% (145 out of 250)

Industry: Medical - Products

View All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Insulet (PODD) Down 0.1% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research Published on December 04,2020

Insulet (PODD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

PODDPositive Net Change

Insulet (PODD) Q3 Earnings & Revenues Top Estimates, View Up

by Zacks Equity Research Published on November 05,2020

Insulet's (PODD) Q3 gross margin improvement can be primarily attributed to performance of the company's U.S. manufacturing and favorable revenue mix from the shift to higher volume

Insulet (PODD) Beats Q3 Earnings and Revenue Estimates

by Zacks Equity Research Published on November 04,2020

Insulet (PODD) delivered earnings and revenue surprises of 183.33% and 5.81%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

PODDPositive Net Change

Earnings Preview: Insulet (PODD) Q3 Earnings Expected to Decline

by Zacks Equity Research Published on October 28,2020

Insulet (PODD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

PODDPositive Net Change

DexCom (DXCM) Q3 Earnings and Revenues Surpass Estimates

by Zacks Equity Research Published on October 28,2020

DexCom's (DXCM) third-quarter results benefit from solid segmental performance.

medical

Masimo (MASI) Earnings and Revenues Beat Estimates in Q3

by Zacks Equity Research Published on October 28,2020

Masimo (MASI) continues to gain from key Product segment, which witnessed solid growth in Q3.

Varian (VAR) Earnings and Revenues Surpass Estimates in Q4

by Zacks Equity Research Published on October 28,2020

Varian's (VAR) receipt of 10 Ethos orders in Q4 instills optimism

LabCorp (LH) Q3 Earnings Beat Estimates, Margins Expand

by Zacks Equity Research Published on October 27,2020

LabCorp (LH) Diagnostics business in Q3 grows significantly on organic volume improvements as a result of growing demand for COVID-19 testing.

Ecolab (ECL) Earnings and Revenues Surpass Estimates in Q3

by Zacks Equity Research Published on October 27,2020

Although Ecolab's (ECL) third-quarter results reflect weakness in the Global Industrial and Institutional segments, its Global Healthcare and Life Sciences unit shows strength.

NextGen Healthcare (NXGN) Gains 8.1% Post Q2 Earnings Beat

by Zacks Equity Research Published on October 26,2020

NextGen (NXGN) benefited from both its operating segments in Q2.

Quest Diagnostics' (DGX) Q3 Earnings Beat, Base Volume Rises

by Zacks Equity Research Published on October 22,2020

In Q3, Quest Diagnostics (DGX) sees strong signs of the health care system returning to pre-pandemic levels

Align Technology (ALGN) Beats on Q3 Earnings, Margins Up

by Zacks Equity Research Published on October 22,2020

Align Technology's (ALGN) segments report solid rebound in sales across geographies despite the pandemic-led business challenges.

Edwards Lifesciences (EW) Beats on Q3 Earnings, Margins Up

by Zacks Equity Research Published on October 22,2020

Despite coronavirus-led business challenges, Edwards Lifesciences (EW) witnessed steady improvement in TAVR procedure volumes in Q3.

medical

Abbott (ABT) Q3 Earnings Top, Diagnostic Test Sales Solid

by Zacks Equity Research Published on October 21,2020

In Q3, Abbott (ABT) registers solid worldwide adoption of FreeStyle Libre System.

Thermo Fisher (TMO) Q3 Earnings Beat on Life Sciences Sales

by Zacks Equity Research Published on October 21,2020

Significant COVID-19 led business expansions, as well as Thermo Fisher's (TMO) base business growth contribute to a stunning Q3 performance.

The Zacks Analyst Blog Highlights: Zoom Video, Entegris, Copart, Insulet and Intuit

by Zacks Equity Research Published on October 14,2020

The Zacks Analyst Blog Highlights: Zoom Video, Entegris, Copart, Insulet and Intuit

HEXO in Focus: Stock Moves 5.2% Higher

by Zacks Equity Research Published on October 13,2020

HEXO saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

PODDPositive Net Change

medical

Nasdaq Set to Outperform 2019 on Digitization Push: 5 Picks

by Nalak Das Published on October 13,2020

This year, the technology sector is leading the V-shaped recovery from the unprecedented health-hazard-led economic devastation.

Abbott's Libre 3 Receives CE Mark, Boosts CGM Prospects

by Zacks Equity Research Published on October 02,2020

Abbott's (ABT) environment-friendly next-generation FreeStyle Libre 3 system aims to provide a better quality of life to diabetics in Europe at the same affordable price of previous systems.